Table 5 Demographic and clinical characteristics of 65 acute myeloid leukemia (AML) patients
From: Acute myeloid leukemia and transcription factors: role of erythroid Krüppel-like factor (EKLF)
Characteristics | Patients |
|---|---|
Gender patients (male/female) | 65 (37/28) |
Age, median (range) | 51 (16-76) |
WBC count (X109/L), median (range) | 13.4 (0.580-292) |
Hemoglobin (g/dL), median (range) | 9.6 (5.6-12.7) |
Platelet count (X109/L), median (range) | 68 (11-538) |
ECOG PS, 0/1/2/3/4 | 17/18/20/9/1 |
FAB | 2/5/11/9/6/12/0/2/2/11 |
10/M1/M2/M3/M4/M5/M6/M7/bilineal/AML-NK/Unclassifiable) | |
WHO | 14/16/3/31 |
current genetic abnormalities/multilineage dysplasia/therapy-related/not otherwise categorized) | |
De novo AML/Secondary AML | 51/14 |
Cytogenetic risk group, (MRC) unfavorable/intermediate/unfavorable/no cytogenetic information) | 15/31/12/7 |
Blasts in peripheral blood (%), median (range) | 32.5 (2-98) |
Blasts in bone marrow (%), median (range) | 79 (20-100) |
Alterations in Chromosome 5/Chromosome 7/Chromosome11/without results | 7 (11.9%)/7 (11.9%)/11 (22.9%)/6 |
Blast CD34+ (YES/NO) | 33/31 |
Blast CD117 (YES/NO) | 41/23 |
Blast CD56+ YES/NO) | 11/54 |
Blast CD133+(YES/NO) | 20/27 |
Blast CD123+( YES/NO) | 12/23 |
Blast HLA-DR+(YES/NO) | 34/21 |
Patient eligible/not eligible for treatment | 50/15 |